Rizatriptan

From Wikipedia, the free encyclopedia


Rizatriptan
Systematic (IUPAC) name
N,N-dimethyl-2- [5-(1,2,4-triazol-1-ylmethyl)- 1H-indol-3-yl]ethanamine
Identifiers
CAS number	145202-66-0
ATC code	N02CC04
PubChem	5078
DrugBank	APRD00008
Chemical data
Formula	C₁₅H₁₉N₅
Mol. mass	269.345 g/mol
Pharmacokinetic data
Bioavailability	45%
Protein binding	14%
Metabolism	by monoamine oxidase
Half life	2–3 hours
Excretion	82% urine; 12% feces
Therapeutic considerations
Pregnancy cat.	C
Legal status
Routes	Oral

Indicated for:

migraine headache with or without aura

Contraindications:

Side effects:

Severe:

Atypical sensations:

paresthesia

Cardiovascular:

Ear, nose, and throat:

tinnitus
sensitivity to noise
sinusitis
allergic rhinitis
upper respiratory inflammation

Gastrointestinal:

diarrhea

Muscular:

myalgia

Neurological:

Respiratory:

dyspnea

Skin:

sweating

Miscellaneous:

hypersensitivity

Rizatriptan (Maxalt®) is a triptan drug developed by Merck & Co. for the treatment of migraine headaches. It is available in strengths of 5 and 10 mg as tablets and orally disintegrating tablets (Maxalt-MLT).

Maxalt obtained approval by the United States Food and Drug Administration (FDA) on June 29, 1998. It is a second-generation triptan.

Rizatriptan is available only by prescription in the United States and Canada. Similarly, it is classed as a POM (Prescription Only Medicine) in the United Kingdom.

This medication is used to treat acute migraine attacks. It does not prevent future migraine attacks.

[edit] External links

Maxalt Official homepage by Merck & Co.
Maxalt Information Fact Sheet
Rizatriptan

v • d • e

Triptans (N02CC)

Almotriptan, Eletriptan, Frovatriptan, Naratriptan, Rizatriptan, Sumatriptan, Zolmitriptan

v • d • e

Tryptamines -

v • d • e Merck & Co., Inc.
Corporate Directors: Lawrence Bossidy \| William Bowen \| Richard Clark \| Johnnetta Cole \| William Harrison \| William Kelley \| Rochelle Lazarus \| Thomas Shenk \| Anne Tatlock \| Samuel Thier \| Wendell Weeks \| Peter Wendell
Key products: Indinavir \| Aprepitant \| Alendronate \| Rizatriptan \| Finasteride \| Montelukast \| Rofecoxib \| Ezetimibe/simvastatin \| Ezetimibe \| Simvastatin \| The Merck Index \| The Merck Manual
Annual Revenue: $22.9 billion USD (2% FY 2004) \| Employees: 63,000 \| Stock Symbol: NYSE: MRK \| Website: www.merck.com